Greenwich LifeSciences, Inc.
GLSINASDAQHealthcareBiotechnology
Previous close
$16.67
+$1.36 · +8.88%
Pre-market
$16.67
$0.00 · 0.00%
Aug 24, 8:16 AM ET
GLSI company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
27
Expensive
Momentum
29
Weakening
Sentiment
43
Mixed
Risk resilience
32
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteGreenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Snehal S. Patel
- Listed since
- Sep 25, 2020
- Employees
- 13
Market position
Day range
Current $16.67
52-week range
Current $16.67
- Open
- $16.16
- Previous close
- $15.31
- Volume
- 176.79K
- 1.18× average
- Average volume
- 149.56K
- Average daily volume
- Market cap
- 244.69M USD
- Beta
- 1.45
- Market reference 1
- 50-day average
- $18.0331
- -7.56% below average
- 200-day average
- $20.7008
- -19.47% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 278.19M USD
- EV / EBITDA
- -14.37×
- Earnings yield
- -6.81%
- Free cash flow yield
- -3.49%
Profitability & efficiency
- Return on equity
- -5480.55%
- Return on assets
- -313.34%
- Return on invested capital
- -5505.94%
Financial health
- Current ratio
- 1.06×
Earnings
- EPS beat rate
- 27%
- 3 beats, 5 misses, 3 met estimates
- Average EPS surprise
- -19.53%
- 11 comparable reports
- Latest EPS result
- -0.27
- Estimate -0.33 · Beat by 18.18%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
GLSI peers
ETFs holding GLSI
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM2.72M0.00%81.62B USD0.19%$299.96+0.77%
Vanguard Morningstar Total Stock Market ETFVTI2.69M0.00%2.3T USD0.03%$378.24+0.44%
Vanguard Extended Market ETFVXF975.62K0.00%93.7B USD0.05%$245.53+0.82%
iShares Russell 2000 Growth ETFIWO968.65K0.01%15.16B USD0.24%$387.37+1.24%
Vanguard U.S. Momentum Factor ETFVFMO804.04K0.04%1.8B USD0.13%$232.52+0.68%
Vanguard Russell 2000 ETFVTWO511.77K0.00%17.4B USD0.06%$121.25+0.74%
iShares Micro-Cap ETFIWC365.39K0.02%1.53B USD0.60%$198.39+1.10%
Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSC138.75K0.01%1.09B USD0.20%$91.32+0.82%iShares Russell 2000 ETFIWM- Market value
- 2.72M
- Weight
- 0.00%
- AUM
- 81.62B USD
- Expense ratio
- 0.19%
- Price / 1D
- $299.96+0.77%
Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 2.69M
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
Vanguard Extended Market ETFVXF- Market value
- 975.62K
- Weight
- 0.00%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
iShares Russell 2000 Growth ETFIWO- Market value
- 968.65K
- Weight
- 0.01%
- AUM
- 15.16B USD
- Expense ratio
- 0.24%
- Price / 1D
- $387.37+1.24%
Vanguard U.S. Momentum Factor ETFVFMO- Market value
- 804.04K
- Weight
- 0.04%
- AUM
- 1.8B USD
- Expense ratio
- 0.13%
- Price / 1D
- $232.52+0.68%
Vanguard Russell 2000 ETFVTWO- Market value
- 511.77K
- Weight
- 0.00%
- AUM
- 17.4B USD
- Expense ratio
- 0.06%
- Price / 1D
- $121.25+0.74%
iShares Micro-Cap ETFIWC- Market value
- 365.39K
- Weight
- 0.02%
- AUM
- 1.53B USD
- Expense ratio
- 0.60%
- Price / 1D
- $198.39+1.10%
Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSC- Market value
- 138.75K
- Weight
- 0.01%
- AUM
- 1.09B USD
- Expense ratio
- 0.20%
- Price / 1D
- $91.32+0.82%
Continue in GoAI
Research GLSIresearch.disclaimer